Receipt of GMP Grade Monepantel Tablets for Phase IIDog Cancer Trials
• GMP monepantel tablets arrive from US to subsidiary Epichem Pty Ltd
• Stability studies for shelf-life support commencement of trial
• Shipment of tablets to veterinarians scheduled to commence next week
• Anti-cancer testing to commence in dogs with B cell lymphoma26 August 2019 – Perth, Australia: PharmAust Ltd (ASXAA), a clinical-stage oncologycompany, is pleased to announce the receipt of 7,750 of its newly developed GMP grademonepantel tablets.
The tablets have been logged into Epichem’s inventory receipt systemsready for shipment to veterinarians conducting the phase II trial as required. Delivery to theveterinarians is expected to commence this week.Shipment of the GMP monepantel tablets has occurred following rigorous tests demonstratingthat all tablets produced in the scaled manufacturing run are consistent in their size, shape andcontent.
Furthermore, the tablets have been on accelerated stability studies and shown to passshelf-life requirements supporting that their performance will not be compromised underhandling conditions expected following distribution to veterinarians and then to pet owners.
PharmAust’s Chief Scientific Officer Dr Richard Mollard commented, “PharmAust is pleased toaccept delivery of the newly developed tablets on schedule at its Epichem facility. Furthermore,PharmAust is looking forward to providing these tablets to veterinarians and commencing thePhase II study, testing anti-cancer efficacy in pet dogs with B cell lymphoma
- Forums
- ASX - By Stock
- NUZ
- Ann: Receipt of GMP Grade Tablets for Phase II Trials
Ann: Receipt of GMP Grade Tablets for Phase II Trials, page-5
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NUZ (ASX) to my watchlist
(20min delay)
|
|||||
Last
18.5¢ |
Change
-0.015(7.50%) |
Mkt cap ! $90.96M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 18.5¢ | $115.7K | 598.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 593392 | 18.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.0¢ | 4355 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 593392 | 0.185 |
8 | 337474 | 0.180 |
5 | 145797 | 0.175 |
4 | 130250 | 0.170 |
1 | 60000 | 0.165 |
Price($) | Vol. | No. |
---|---|---|
0.190 | 4355 | 1 |
0.200 | 77907 | 4 |
0.205 | 109808 | 2 |
0.210 | 147252 | 4 |
0.215 | 100000 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
NUZ (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online